Business UpdateJun 4, 2026, 01:06 PM
PatentVest Report: Muscle-Preservation Expands GLP-1 Obesity Opportunity
AI Summary
PatentVest, a division of MDB Capital Holdings, announced the release of its report, "The Muscle Problem: How Myostatin Could Expand the GLP-1 Opportunity." The study analyzes the emerging muscle-preservation category in obesity therapeutics, identifying 20 programs in development. It highlights strategic acquisitions by major pharmaceutical companies and suggests that these therapies will enhance GLP-1 treatment outcomes by improving body composition, creating new partnering, licensing, and IP opportunities.
Key Highlights
- PatentVest released a report on muscle-preservation programs in obesity treatment.
- 20 muscle-preservation programs are currently in development.
- Eli Lilly acquired Versanis Bio and AstraZeneca acquired SixPeaks Bio, highlighting category confidence.
- Muscle-preservation therapies are expected to complement GLP-1s, improving body composition.
- Intellectual property positioning, including combination therapy patents, is becoming valuable.
Price Impact
More from MDBH